Medicus Pharma Ltd. Common Stock Price & Performance (MDCX)

Medicus Pharma has reported over 60% complete clinical clearance in its Phase 2 trial for basal cell carcinoma (BCC). The non-invasive microneedle patch showed strong safety, with no dose-limiting toxicities. Interim findings will be submitted to the FDA as the company seeks to expedite the regulatory process.123

Medicus Pharma plans to request a Type C meeting with the FDA in Q2 2025 following encouraging interim results from its Phase 2 study. The trial, targeting 60 patients, demonstrated significant clinical clearance and safety, highlighting the potential of its microneedle patch as a non-invasive BCC treatment.432

Medicus Pharma has submitted plans for a Phase 2 clinical trial in the UAE for its microneedle patch treating basal cell carcinoma. This follows strong U.S. trial progress, with over 50% of patients randomized. The company aims to broaden international market opportunities while advancing U.S. FDA discussions.234